Transcranial magnetic stimulation (TMS) is increasingly being applied to effectively treat mental illness, however efforts to quantify the effects of TMS on the network architecture of the brain have largely been limited in scope and tied to specific neurologic and psychiatric disorders. The objective of the current work is to build and validate a whole-brain, domain-general model of brain connectivity changes following TMS, based on physical models of the current distribution at the cortex. PUBLIC HEALTH RELEVANCE: This work is relevant to public health because it will provide direct evidence that brain connectivity changes following neuromodulatory TMS vary as a function of the current density at the cortex, which can be used to predict psychiatric symptom change following neuromodulatory TMS.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Male breast cancer (MBC) is rare, comprising only 1% of all breast malignancies. Due to lack of clinical trial data, treatment of MBC is largely extrapolated from current guidelines on management of female breast cancer (FBC). This study aims to investigate current treatment patterns in MBC. An anonymous online survey will be sent via Society of Surgical Oncology (SSO) to practicing surgeons across the United States and worldwide.

This trial is testing V940 given with or without MK-3475A in people: Whose non-small cell lung cancer (NSCLC) was fully removed with surgery, and Who may have an increased chance of their cancer coming back.

This is a randomized, double-blind, Phase 3 study that will compare the efficacy and safety of INCB161734 plus chemotherapy versus placebo plus chemotherapy in participants with metastatic KRAS G12Dmutated PDAC who have received no prior systemic therapy for metastatic disease. The chemotherapy used throughout the study for each participant will consist of investigator's choice of 1 of 2 standard chemotherapy regimens: mFOLFIRINOX or GemNabP.